Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVER-52 trial of RVU120 in relapsed or refractory high-risk myelodysplastic syndrome or acute myeloid leukemia
2023-505910-10-00Phase 2Completed
- Sponsor
- Ryvu Therapeutics
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of rvu120 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 cohorts), sponsored by Ryvu Therapeutics. Primary endpoint: Complete remission rate. Started Jan 2024; status: completed.
02
Drugs
rvu120
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2023-505910-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505910-10-00.